TTOO — T2 Biosystems Share Price
0.000.00%
Last trade - 00:00- $2.97m
- $12.81m
- $7.19m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.39 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -542.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8.34 | 18.13 | 28.06 | 22.3 | 7.19 | 10.6 | 23.1 | -7.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
Directors
- John Sperzel CHM (58)
- John Sprague CFO (62)
- Alec Barclay COO (40)
- Michael Gibbs VPR (50)
- Aparna Ahuja OTH (53)
- Brett Giffin OTH
- Anthony Pare OTH (59)
- John Cumming LED (75)
- Laura Adams DRC
- Seymour Liebman DRC (72)
- Thierry Bernard IND (56)
- David Elsbree IND (71)
- Ninfa Saunders IND (69)
- Robin Toft IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- April 27th, 2006
- Public Since
- August 7th, 2014
- No. of Shareholders
- 13
- No. of Employees
- 113
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 28,045,417
- Address
- 101 Hartwell Ave, LEXINGTON, 02421-3125
- Web
- https://www.t2biosystems.com/
- Phone
- +1 7814571200
- Contact
- Philip Taylor
- Auditors
- BDO USA, LLP
Upcoming Events for TTOO
Q2 2025 T2 Biosystems Inc Earnings Release
Q3 2025 T2 Biosystems Inc Earnings Release
Similar to TTOO
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
What is the T2 Biosystems share price?
As of Today at 23:32 UTC, shares in T2 Biosystems are trading at $0.11. This share price information is delayed by 15 minutes.
How has the T2 Biosystems share price performed this year?
Shares in T2 Biosystems last closed at $0.11 and the price had moved by -96.39% over the past 365 days. In terms of relative price strength the T2 Biosystems share price has underperformed the S&P500 Index by -96.59% over the past year.
What are the analyst and broker recommendations for T2 Biosystems?
The overall consensus recommendation for T2 Biosystems is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the T2 Biosystems dividend yield?
T2 Biosystems does not currently pay a dividend.
Does T2 Biosystems pay a dividend?
T2 Biosystems does not currently pay a dividend.
When does T2 Biosystems next pay dividends?
T2 Biosystems does not currently pay a dividend.
How do I buy T2 Biosystems shares?
To buy shares in T2 Biosystems you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of T2 Biosystems?
As of the previous close price of $0.11, shares in T2 Biosystems had a market capitalisation of $2.97m.
Where are T2 Biosystems shares listed?
Here are the trading details for T2 Biosystems:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: TTOO
What kind of share is T2 Biosystems?
Based on an overall assessment of its quality, value and momentum T2 Biosystems is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a T2 Biosystems share price forecast for 2025?
The analyst consensus target price for shares in T2 Biosystems is $5.00. That is 4616.98% above the last closing price of $0.11.
Analysts covering T2 Biosystems currently have a consensus Earnings Per Share (EPS) forecast of -$3.10 for the next financial year.
Find out moreWhat is the trend in the T2 Biosystems share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like T2 Biosystems. Over the past six months, its share price has underperformed the S&P500 Index by -91.82%.
As of the last closing price of $0.11, shares in T2 Biosystems were trading -93.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the T2 Biosystems PE Ratio?
The T2 Biosystems PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of T2 Biosystems?
T2 Biosystems' management team is headed by:
- John Sperzel - CHM
- John Sprague - CFO
- Alec Barclay - COO
- Michael Gibbs - VPR
- Aparna Ahuja - OTH
- Brett Giffin - OTH
- Anthony Pare - OTH
- John Cumming - LED
- Laura Adams - DRC
- Seymour Liebman - DRC
- Thierry Bernard - IND
- David Elsbree - IND
- Ninfa Saunders - IND
- Robin Toft - IND